Radiosurgery Society® Webinar on MR-Guided Stereotactic Body Radiation Therapy Yields Record Attendance

MRIdian® Users Highlight Clinical Implementation, Image Quality and Adaptive Therapy

Sep 02, 2015, 08:30 ET from ViewRay, Inc.

CLEVELAND, Sept. 2, 2015 /PRNewswire/ -- ViewRay, Inc. (OTCQB:VRAY) announced today highlights from a webinar titled "Clinical Implementation of MR-IGRT for Stereotactic Body Radiotherapy", hosted by the Radiosurgery Society®, a non-profit organization dedicated to advancing the science and clinical practice of radiosurgery, which was held on Thursday, August 20. A recording of the webinar and a condensed five-minute version are available at

The one-hour webinar featured users of the MRIdian System, discussing their clinical experience with the world's first and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously. The event drew nearly 200 participants interested in learning more about MR-guided stereotactic body radiotherapy (SBRT), the treatment of cancer using higher doses of radiation in a shorter course of therapy than traditional radiation therapy, delivered under MRI guidance to enable soft-tissue visualization and on-table adaptive treatments.

Daniel Low, Ph.D., Professor and Vice Chair of Physics in the Radiation Oncology Department at UCLA Health moderated the webinar, which included presentations by Clifford Robinson, M.D., Associate Professor in the Department of Radiation Oncology and Chief of the Stereotactic Body Radiation Therapy program; and Rojano Kashani, Ph.D., Assistant Professor, Radiation Oncology, both from the Washington University School of Medicine in St. Louis, Mo.

Drs. Robinson and Kashani discussed their implementation of an MR-guided SBRT program using the MRIdian System at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. Patient treatments began in January 2014 and Dr. Kashani shared that they're treating lesions in the majority of sites for which radiotherapy is indicated.  Today, more than 20 percent of patients treated on the MRIdian at Siteman Cancer Center are treated using SBRT.

Dr. Kashani's portion of the presentation focused on commissioning and quality assurance, physics workflows for adaptive radiotherapy, and the use of MR-guided gating. She highlighted the quality of the system's volumetric soft-tissue images for pre-treatment positioning and the accuracy of the dose prediction for quality assurance and plan adaptation.

Dr. Robinson discussed various studies and protocols currently underway exploring the use of MR-guided SBRT to treat lesions throughout the body. He described the clinical workflow and the benefits of the system's plan comparison tool in streamlining the renormalizing process. He shared case examples where changes in the patients' anatomy were noticed on the day of treatment and the ability to adapt treatment while the patient was on the table allowed doctors to focus more dose to the tumor and minimize damage to surrounding healthy tissue, resulting in a dramatic reduction in tumor size post-treatment.

"Use of SBRT for inoperable, unresectable and now oligometastatic disease is really taking off and while we'd love to be able to deliver that type of dosing to almost all lesions, the proximity and sensitivity of nearby organs at risk is an issue," said Dr. Robinson. "We believe MR-guided SBRT may improve that therapeutic ratio with online adaptive treatments, which enable real-time imaging, contouring, optimization and quality assurance while the patient is on the table."

"The Radiosurgery Society® is committed to furthering the field of radiosurgery and SBRT through education and the sharing of clinical data," said Joanne Davis, Ph.D., Executive Director of the Radiosurgery Society. "MR-guided SBRT is a topic of great interest amongst the radiation oncology and medical physics community and we're pleased by the significant response to our webinar and the opportunity it provided to share valuable clinical information."

The Radiosurgery Society® is a multi-disciplinary non-profit organization of surgeons, radiation oncologists, physicists and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery. The Radiosurgery Society represents more than 500 members who perform stereotactic radiosurgery and SBRT in hospitals and freestanding centers throughout the world. More information about the Radiosurgery Society can be found at

About ViewRay

ViewRay, Inc. of Cleveland, Ohio, is a medical device company developing advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

Forward Looking Statements:

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the use of SBRT and MR-guided SBRT and to ViewRay's technologies. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize MRIdian, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at


SOURCE ViewRay, Inc.